Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment

NCT03096782 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03096782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03096782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
October 13, 2017
Completion date
September 20, 2022
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase chronic myelogenous leukemia, bcr-abl1 positive, acute biphenotypic leukemia, acute leukemia, acute lymphoblastic leukemia, acute lymphoblastic leukemia in remission, acute myeloid leukemia, acute myeloid leukemia arising from previous myelodysplastic syndrome, chemotherapy-related leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, bcr-abl1 positive, chronic myelomonocytic leukemia, hodgkin lymphoma, langerhans cell histiocytosis, minimal residual disease, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, non-hodgkin lymphoma, recurrent hodgkin lymphoma, refractory acute lymphoblastic leukemia, refractory myelodysplastic syndrome, small lymphocytic lymphoma, therapy-related myelodysplastic syndrome